PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403457
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403457
According to Stratistics MRC, the Global Western Blotting Market is accounted for $1.18 billion in 2023 and is expected to reach $2.11 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Protein analysis and detection are common applications of the molecular biology technique known as western blotting. It involves transferring the separated proteins onto a membrane after they have been separated by size using gel electrophoresis. Numerous scientific domains utilize western blotting to aid in the investigation of protein expression, post-translational modifications, and interactions.
According to data published by the Centers for Disease Control and Prevention (CDC), stated that in 2020, 30,635 people received an HIV diagnosis in the U.S.
The study of cellular processes, protein expression, and interactions is greatly aided by western blotting, which provides important new understandings in fields like neurobiology and cancer. It is essential as the field of biomedical research grows and the need for precise protein analysis increases. Furthermore, its versatility in exploring diseases, understanding molecular mechanisms, and validating research findings positions it as a fundamental tool, to meet the evolving demands of the biomedical research community which is driving adoption and innovation of this market's growth.
The cost of Western blotting can be attributed to several reasons, such as the fact that the procedure necessitates the use of costly reagents and consumables, including blocking agents, detection substrates, and antibodies. Specialized tools like imaging equipment and gel electrophoresis systems also raise the overall cost. Furthermore, the cost of using the technique is further increased by the requirement for skilled personnel. The high expense of carrying out these tests is one significant obstacle to the market.
Initiatives from government bodies, such as the National Institutes of Health (NIH), allocate funds to projects involving Western blotting techniques. Innovation, technical progress, and the investigation of novel uses in biomedicine, medication development, and diagnostics are all encouraged by this support. Furthermore, the financial support creates a favorable environment for developments in protein analysis and related research, speeds up scientific discoveries, and supports by improving accessibility which is driving this market expansion.
Incompatibilities across laboratories in procedures, reagents, and equipment hinder result reproducibility. Variability in methodologies impacts data reliability, making it challenging for researchers to compare and validate findings. Problems with standardization can damage Western blotting's image, raising doubts regarding the accuracy of the data and making it more difficult for research groups to collaborate.
Disruptions in supply chains, logistical challenges, and restrictions on laboratory activities have hindered the production and distribution of Western blotting reagents and instruments. Many research projects were delayed or halted due to lockdowns, impacting the demand for these products. Furthermore, the resources available for Western blotting studies have been restricted due to decreased funding for research irrelevant to COVID-19. Eventually, attention and resources have been diverted from other areas due to the shift in research priorities towards COVID-19. Economic uncertainties have prompted cost-consciousness, affecting purchasing decisions in the scientific community.
The instrument segment is estimated to hold the largest share due to its crucial role in molecular biology and protein research. They play a pivotal role in the precise separation, transfer, and detection of proteins from complex biological samples. Manufacturers continually innovate to provide researchers with state-of-the-art systems, incorporating features like rapid electrophoresis, semi-dry or wet transfer capabilities, and advanced imaging technologies. Furthermore, these instruments include electrophoresis systems for separating proteins based on size, transfer systems for transferring proteins, and imaging systems for visualizing and quantifying protein bands, which is driving this segment expansion.
The biopharmaceutical & biotechnology companies segment is anticipated to have highest CAGR during the forecast period due to the use of these companies for protein analysis in drug development, quality control, and research processes. The technique aids in assessing protein expression, validating therapeutic targets, and ensuring product consistency. Additionally, by providing precise insights into protein characteristics, it supports the development of biopharmaceuticals and the advancement of biotechnological research. It represents a key stakeholder group in the development and production of biotherapeutics, thereby boosting this segment's growth.
North America commanded the largest market share during the extrapolated period owing to government programs that support scientific research and development, especially in the biotechnology and healthcare sectors. Collaborations between academic institutions, research organizations, and industry players foster innovation and applications. Furthermore, these now meet quality standards set by regulatory frameworks established by organizations such as the Food and Drug Administration (FDA), guaranteeing dependability in research and diagnostics, thereby propelling this region's size.
Europe is expected to witness highest CAGR over the projection period due to advancements in detection technologies, transfer strategies, and gel electrophoresis systems in life sciences research. These procedures are now more accurate and efficient European policies promoting research and development, coupled with initiatives supporting biotechnology and healthcare innovation. Some of the key players including Boster Biological Technology, GE Healthcare, PerkinElmer Inc. and Danaher Corporation contribute to strict regulatory policies and quality standards which are driving this region's growth.
Some of the key players in the Western Blotting Market include Abcam Plc, Advansta, Inc., Azure biosystems, inc., Bio-Techne Corporation, Boster Biological Technology, Cell signaling technology, inc., Danaher Corporation, EMD Millipore Corporation, GE Healthcare, Hofmann-La Roche Ltd., LI-COR, Inc., Merck Kgaa, PerkinElmer Inc., Stressmarq biosciences inc. and Thermo Fisher Scientific, Inc.
In November 2023, GE HealthCare and Masimo announced a joint agreement to integrate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCare's Portrait Mobile wireless and wearable patient monitoring solution.
In October 2023, Thermo Fisher Scientific and Olink announced that their respective boards of directors have approved Thermo Fisher's proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash.
In October 2023, GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase. As clinicians work to treat CVD, cardiology procedures continue to evolve as demand for minimally invasive surgery grows.